Literature DB >> 21880043

Proteomic analyses of human plasma: Venus versus Mars.

Christopher C Silliman1, Monika Dzieciatkowska, Ernest E Moore, Marguerite R Kelher, Anirban Banerjee, Xiayuan Liang, Kevin J Land, Kirk C Hansen.   

Abstract

BACKGROUND: Plasma is vital for the resuscitation of injured patients and to restore necessary procoagulants, especially Factors (F)II, FV, FVII, FX, and FXIII; however, female plasma has been implicated in the majority of transfusion-related acute lung injury (TRALI) cases and male-only plasma transfusion regimens have significantly decreased the incidence of TRALI. Little is known about the human plasma proteome, and no comparisons have been made between male and female plasma; therefore, we hypothesize that there are significant differences between plasma from male and female donors. STUDY DESIGN AND METHODS: Five units of fresh-frozen plasma each were collected from nulliparous female donors and male donors, and the proteome was analyzed by depleting the 14 most common proteins by immunoaffinity columns followed by protein separation by one dimension gel electrophoresis, tryptic digestion of the proteins, analysis of the peptides by liquid chromatography-tandem mass spectrometry, and identification employing human protein sequence databases.
RESULTS: Female plasma versus male plasma contained pregnancy zone protein (419- to 580-fold), FV (twofold), α(1)-antitrypsin (twofold), β(2) -microglobulin (twofold), and Complement Factors H and C4B (1.5- to 2-fold) at significantly higher concentrations than males and males contained significant increases in Fc-binding protein (twofold), protein Z-dependent protease inhibitor (twofold), phosphatidylinositol glycan-specific phospholipase (fourfold), protein S-100 (threefold), and transgelin-2 (14-fold) versus females (p < 0.005). The increases in FV, α(1)-antitrypsin, and β(2)-microglobulin were confirmed by an activity assay or immunoblots.
CONCLUSION: We conclude that there are proteomic differences between male and female plasma, which could be exploited to improve clinical outcomes in transfused patients.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880043      PMCID: PMC3235251          DOI: 10.1111/j.1537-2995.2011.03316.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  47 in total

1.  HEMOSTASIS IN FACTOR V DEFICIENCY.

Authors:  W P WEBSTER; H R ROBERTS; G D PENICK
Journal:  Am J Med Sci       Date:  1964-08       Impact factor: 2.378

2.  Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations.

Authors:  Eleftherios P Diamandis; Da-Elene van der Merwe
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

3.  B-1 cells express transgelin 2: unexpected lymphocyte expression of a smooth muscle protein identified by proteomic analysis of peritoneal B-1 cells.

Authors:  Rubén Francés; Joseph R Tumang; Hiroaki Kaku; Sean M Gurdak; Thomas L Rothstein
Journal:  Mol Immunol       Date:  2006-02-17       Impact factor: 4.407

4.  Evidence for functional heterogeneity in IgG Fc-binding proteins associated with group A streptococci.

Authors:  R Raeder; E L Faulmann; M D Boyle
Journal:  J Immunol       Date:  1991-02-15       Impact factor: 5.422

Review 5.  [Role of S-100 protein in the function of brain cell nuclei].

Authors:  V I Tiulenev; A A Kapralov; Ia V Belik
Journal:  Ukr Biokhim Zh (1978)       Date:  1996 May-Jun

Review 6.  The coagulopathy of massive transfusion.

Authors:  J-F Hardy; P de Moerloose; C M Samama
Journal:  Vox Sang       Date:  2005-10       Impact factor: 2.144

Review 7.  Structures of bacterial immunoglobulin-binding domains and their complexes with immunoglobulins.

Authors:  M Tashiro; G T Montelione
Journal:  Curr Opin Struct Biol       Date:  1995-08       Impact factor: 6.809

8.  Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

Authors:  Daniel W Cramer; Robert C Bast; Christine D Berg; Eleftherios P Diamandis; Andrew K Godwin; Patricia Hartge; Anna E Lokshin; Karen H Lu; Martin W McIntosh; Gil Mor; Christos Patriotis; Paul F Pinsky; Mark D Thornquist; Nathalie Scholler; Steven J Skates; Patrick M Sluss; Sudhir Srivastava; David C Ward; Zhen Zhang; Claire S Zhu; Nicole Urban
Journal:  Cancer Prev Res (Phila)       Date:  2011-03

9.  Serum neopterin, beta2-microglobulin, soluble interleukin-2 receptors, and immunoglobulin levels in healthy adolescents.

Authors:  T Satoh; L M Brown; W A Blattner; E M Maloney; C C Kurman; D L Nelson; D Fuchs; H Wachter; D J Tollerud
Journal:  Clin Immunol Immunopathol       Date:  1998-08

10.  Physical and functional association of cytosolic inositolphospholipid-specific phospholipase C of calf thymocytes with a GTP-binding protein.

Authors:  P Wang; S Toyoshima; T Osawa
Journal:  J Biochem       Date:  1987-11       Impact factor: 3.387

View more
  19 in total

1.  Variation and quantification among a target set of phosphopeptides in human plasma by multiple reaction monitoring and SWATH-MS2 data-independent acquisition.

Authors:  Anna M Zawadzka; Birgit Schilling; Jason M Held; Alexandria K Sahu; Michael P Cusack; Penelope M Drake; Susan J Fisher; Bradford W Gibson
Journal:  Electrophoresis       Date:  2014-07-10       Impact factor: 3.535

2.  Methylation potential associated with diet, genotype, protein, and metabolite levels in the Delta Obesity Vitamin Study.

Authors:  Jacqueline Pontes Monteiro; Carolyn Wise; Melissa J Morine; Candee Teitel; Lisa Pence; Anna Williams; Beverly McCabe-Sellers; Catherine Champagne; Jerome Turner; Beatrice Shelby; Baitang Ning; Joan Oguntimein; Lauren Taylor; Terri Toennessen; Corrado Priami; Richard D Beger; Margaret Bogle; Jim Kaput
Journal:  Genes Nutr       Date:  2014-04-24       Impact factor: 5.523

3.  Habitual aerobic exercise and circulating proteomic patterns in healthy adults: relation to indicators of healthspan.

Authors:  Jessica R Santos-Parker; Keli S Santos-Parker; Matthew B McQueen; Christopher R Martens; Douglas R Seals
Journal:  J Appl Physiol (1985)       Date:  2018-09-20

Review 4.  Trauma-Induced Coagulopathy: An Institution's 35 Year Perspective on Practice and Research.

Authors:  E Gonzalez; E E Moore; H B Moore; M P Chapman; C C Silliman; A Banerjee
Journal:  Scand J Surg       Date:  2014-04-30       Impact factor: 2.360

Review 5.  TACTIC: Trans-Agency Consortium for Trauma-Induced Coagulopathy.

Authors:  K G Mann; K Freeman
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

6.  Plasma first in the field for postinjury hemorrhagic shock.

Authors:  Ernest E Moore; Theresa L Chin; Michael C Chapman; Eduardo Gonzalez; Hunter B Moore; Christopher C Silliman; Kirk C Hansen; Angela Sauaia; Anirban Banerjee
Journal:  Shock       Date:  2014-05       Impact factor: 3.454

7.  Taking the Blood Bank to the Field: The Design and Rationale of the Prehospital Air Medical Plasma (PAMPer) Trial.

Authors:  Joshua B Brown; Francis X Guyette; Matthew D Neal; Jeffrey A Claridge; Brian J Daley; Brian G Harbrecht; Richard S Miller; Herb A Phelan; Peter W Adams; Barbara J Early; Andrew B Peitzman; Timothy R Billiar; Jason L Sperry
Journal:  Prehosp Emerg Care       Date:  2015-02-06       Impact factor: 3.077

Review 8.  Is Coagulopathy an Appropriate Therapeutic Target During Critical Illness Such as Trauma or Sepsis?

Authors:  Hunter B Moore; Robert D Winfield; Mayuki Aibiki; Matthew D Neal
Journal:  Shock       Date:  2017-08       Impact factor: 3.454

9.  It's not your grandfather's field plasma.

Authors:  Luis Lee; Ernest E Moore; Kirk C Hansen; Christopher C Silliman; James G Chandler; Anirban Banerjee
Journal:  Surgery       Date:  2012-11-02       Impact factor: 3.982

10.  Proteomic analysis of the supernatant of red blood cell units: the effects of storage and leucoreduction.

Authors:  M Dzieciatkowska; C C Silliman; E E Moore; M R Kelher; A Banerjee; K J Land; M Ellison; F B West; D R Ambruso; K C Hansen
Journal:  Vox Sang       Date:  2013-05-11       Impact factor: 2.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.